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Abstract 
Ovarian cancer is the fifth most common cause of cancer death among women that is mostly 
due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers 
in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal 
transition, in the plasma samples of patients with malignant (n=28) or non-malignant (n=12) 
ovarian tumors and disease-free healthy volunteers (n=60) by qRT-PCR. The expression 
levels of miR200a, miR200b, miR200c, miR141, miR429, miR203a, miR34b (p<0.001) and 
miR34a (p<0.01) were significantly higher in the malignant samples than in healthy controls. 
MiR203a, miR141 (p<0.01), miR200a and miR429 (p<0.05) levels were also higher in 
malignant compared to non-malignant samples. ROC-AUC was the highest in the case of 
miR200c: 0.861 (95%CI=0.776-0.947). Spearman's rank correlation analysis revealed positive 
correlation between the plasma levels of the studied miRNAs that was the highest between 
miR200b and miR200c (rs = 0.774; p<0.001). Target analysis also suggested tight interaction 
between these miRNAs in the regulation of cancer development. The agreement of diagnostic 
tests based on miRNA levels and the standard CA125 or HE4 was weak according to Cohen's 
kappa values. We conclude that miR200 family members, miR34b and miR203a might be 
promising complementary biomarkers in ovarian cancer. 
1. Introduction 
Ovarian cancer is the fifth most common cause of cancer death among women and the most 
lethal form of gynecological malignancy (Siegel et al., 2018). More than 90% of ovarian 
cancers have an epithelial histology and arise from cells that cover the surface of the ovary 
(Feeley and Wells, 2001). The 5-year survival rate ranges from 29 to 93% depending mostly 
on the time of diagnosis (Siegel et al., 2018). This is primarily due to the lack of early and 
specific symptoms. Currently, histopathology examination is considered to be the gold 
standard in the diagnosis of ovarian cancer. However, it has several limitations: it is difficult 
to obtain tumor samples, it is expensive and it is not applicable in the early diagnosis. The use 
of biological fluids such as blood as a source of biomarkers holds great possibilities in modern 
diagnostics. The non-invasive nature of liquid biopsies allows rapid diagnosis and monitoring 
disease progression. Moreover liquid biopsy has the potential to capture the entire genetic 
panorama of the tumor thus it is not influenced by the genetic heterogeneity of the tumor that 
is a great concern in tissue biopsies (Larrea et al., 2016). 
Carbohydrate Antigen-125 (CA125) and Human Epididymis Protein 4 (HE4) are the most 
widely used biomarkers in ovarian cancer diagnosis (Montagnana et al., 2017). However, 
CA125 has low diagnostic sensitivity (50%-62% for early stage ovarian cancer) and limited 
specificity (73%-77%) and it is reported to be elevated in other conditions e.g. in 
menstruation, pregnancy and endometriosis as well (Sölétormos et al., 2016; Montagnana et 
al., 2017). HE4 did not contribute significantly to the improvement of ovarian cancer 
diagnosis either (Van Gorp et al., 2011). Circulating (or cell free) nucleic acids including 
miRNAs also have the potential to be useful diagnostic and prognostic biomarkers. 
MicroRNAs are single stranded small non-coding RNA molecules (̴19-25nt in length), which 
play role in posttranscriptional gene regulation. They are involved in the regulation of cell 
cycle, apoptosis, proliferation and carcinogenesis (Hayes et al., 2014). Circulating miRNAs 
proved to be promising biomarkers in various cancers, including breast, prostate, pancreatic or 
colon cancer (Hayes et al., 2014; Chakraborty et al., 2016; Larrea et al., 2018). MiRNAs are 
frequently dysregulated in ovarian cancer and miRNA expression profiles were shown to be 
reliable markers in the discrimination between ovarian cancer specimens and normal ovaries 
(Kinose et al., 2014). However, only few publications focus on circulating miRNAs in ovarian 
cancer especially in Central or Eastern European populations where the incidence of ovarian 
cancer shows the highest rates (Reid et al., 2017). 
Epithelial-mesenchymal transition (EMT) is a biological process that allows an epithelial cell 
to undergo multiple biochemical changes that result in a mesenchymal phenotype, which lead 
to enhanced migratory capacity (Kalluri and Weinberg, 2009). Ovarian carcinomas arise from 
epithelial cells and EMT is a crucial step in the progression to metastasis. EMT is regulated 
by dozens of transcription factors including members of the Snail and ZEB families. MiRNAs 
are also associated with the regulation of EMT among which miR200 (miR200a, miR200b, 
miR200c, miR141, miR429), miR34 (miR34a, miR34b, miR34c) family members and 
miR203 have well-established roles (Kalluri and Weinberg, 2009; Bracken et al., 2015). Our 
aim was to study the plasma levels of circulating miR200, miR34 family members and 
miR203a as biomarker candidates in epithelial ovarian cancer.  
 
2. Materials and methods 
 
2.1 Patients 
The total of 100 blood samples (60 disease-free healthy control, 28 patients with malignant, 
12 patients with non-malignant ovarian masses) were collected from the Department of 
Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, during 2016-2017. 
All ovarian cancer patients went through surgery and tissue samples were histopathologically 
diagnosed. They did not receive chemotherapy or radiotherapy prior to participation in the 
study. Pathological characterization of ovarian cancer was determined according to the 
International Federation of Gynecology and Obestrics (FIGO) criteria. All participants were 
informed and they signed a consent. The study protocol was approved by the Scientific and 
Research Ethics Committee of the Medical Research Council (ETT TUKEB) [No: 
2379/2014], the research was conducted in accordance with the Declaration of Helsinki. 
Venous blood samples were collected in EDTA tubes and kept at 4°C for less than 2 hours 
until plasma separation. Plasma was separated by two-step centrifugation (2.500g and 
16.000g; 10 min, 4°C). After separation the plasma was homogenized, aliquoted, and stored at 
-80 °C until further processing. 
 
2.2 MiRNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA (including the small non-coding RNAs) was extracted from 200µl plasma 
sample by using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. The miRNA-specific fluorometric assay using a Qubit® 2.0 
Fluorometer (Thermo Fischer Scientific, USA) was used to determine the concentration of 
extracted RNA.  
The miScript PCR System (Qiagen, Hilden, Germany) was used to detect mature miRNAs. 
Reverse transcription of miRNAs was performed by miScript II RT Kit (Qiagen). Quantitative 
real-time PCR was used (Light cycler II. 1.0; Roche GmbH, Mannheim, Germany) to 
determine the level of miR200a-3p, miR200b-3p, miR200c-3p, miR141-3p, miR429-3p, 
miR34a-5p, miR34b-3p, miR34c-3p and miR203a-3p with the miScript SYBR Green PCR 
Kit (Qiagen). The PCR reaction mixture contained 500 pg reverse transcription products. The 
reaction samples were first denatured at 95 °C for 15 min, followed by 50 cycles of 94 °C for 
15 sec, 55°C for 30 sec and 70°C for 30 sec. Finally, a melting curve was generated by taking 
fluorescent measurements every 0.2 °C for 25 s from 50 °C until 95 °C to ensure the detection 
of a single PCR product. Cycle threshold (Ct) values above the determinable range (up to 45) 
were assigned a Ct of 45. All measurements were performed in triplicate and the amounts of 
PCR products were normalized to an internal control (miR103-3p; Kan et al., 2012). Relative 
expression levels were calculated by the 2
-∆Ct
 method.  
 
2.3 Statistical analysis 
Distribution of data was analyzed by Kolmogorov-Smirnov test. Statistical significance of the 
expression data was determined by the Mann–Whitney U test. Spearman rank correlation was 
used to determine the correlation between the expression values of miRNAs (rs–Spearman’s 
rank correlation coefficient). The distribution of CA125 and HE4 values in the malignant and 
non-malignant samples was analyzed by Fisher’s exact test. In the case of selected miRNAs 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 
diagnostic accuracy were calculated. Receiver operating characteristics (ROC) curves and 
areas under the ROC curve (AUC) with corresponding upper and lower 95% confidence 
intervals (95% CI) were generated. In the case of some malignant samples Cohen’s kappa (κ) 
values were calculated to define the agreement between the diagnostic tests based on miRNAs 
and CA125 or HE4. Optimal cut-off points were determined by the ROC analysis based on 
the best balance of sensitivity and specificity. In respect of all tests the significance level was 
p<0.05. 
The statistical analysis was performed by SPSS 25 (SPSS package for Windows, Release 25.; 
SPSS, Chicago, IL, USA). The ROC-AUC graphs were generated with XLSTAT (version 
2017.5, New York, NY, USA). Scatter plot was generated by GraphPad Prism 7. 
 
2.4 Bioinformatic analysis 
To identify experimentally validated target genes of miRNAs the miRTargetLink Human 
miRNA target prediction tool was used (https://ccb-web.cs.uni-
saarland.de/mirtargetlink/multinet.php). Target genes that showed strong interaction with the 
query miRNAs were established for each miRNA separately, then the overlapping network of 
genes targeted by two miRNAs were also generated by the tool. Functional genomic 
annotation was applied with functional clustering analysis on the list of the miRNA target 
genes using the DAVID tool with high stringency option (https://david.ncifcrf.gov; Huang et 
al., 2009). To rank and characterize the significance of the generated Functional Annotation  
Clusters the annotation term p-values and enrichment scores were used. The statistically 
significant enrichment of the common target genes in known biochemical/molecular pathways 
and their GO ontologies were also assessed by the DAVID tool. 
 
3. Results 
 
3.1 Patient characteristics 
A total of 100 participants treated by the Department of Obstetrics and Gynecology, Faculty 
of Medicine, University of Debrecen were involved in this study, including 28 patients with 
malignant epithelial ovarian tumor, 12 patients with non-malignant ovarian masses, and 60 
age-matched healthy volunteers without any ovarian disorder whose samples were used as 
controls in the comparisons. Disease status of all ovarian cancer patients were classified as 
FIGO stage I, III and IV according to imaging studies and surgical pathological findings 
(Table 1). CA125 and HE4 values were available for most of the malignant and non-
malignant samples (Table 1). Fisher’s exact test showed statistically significant difference in 
the distribution of CA125 values between the malignant and non-malignant samples 
(p<0.001). However, the distribution did not prove to be significant in the case of HE4 values 
between these groups (p=0.381). 
 
3.2 Relative expression of plasma miRNAs 
In this study miR200 (miR200a, miR200b, miR200c, miR141, miR429) and miR34 (miR34a, 
miR34b, miR34c) family members together with miR203a were selected as candidate 
biomarkers in the diagnosis of ovarian cancer. MiR103 was chosen as an endogenous 
reference for data normalization (Kan et al. 2012).  
In order to identify those miRNAs that are associated with ovarian cancer the relative 
expression level of miRNAs measured in the malignant and healthy samples were compared. 
The expression level of miR200a, miR200b, miR200c, miR141, miR429, miR34b, miR203a 
(p<0.001) and miR34a (p<0.05) was significantly elevated in the malignant samples (Figure 
1/A and 1/B). However, the plasma level of miR34c did not show significant difference in 
these two groups (p=0.222; Figure1/B).  
We also studied whether these miRNAs are reliable markers in the differential diagnosis of 
non-malignant tumors. For this purpose the relative expression level of these miRNAs was 
also compared between the malignant and non-malignant samples. In this comparison the 
relative expression level was significantly higher in the case of miR203a, miR141 (p<0.01), 
miR200a and miR429 (p<0.05) in the malignant samples (Figure1/A and 1/B). The expression 
level of miR200b, miR200c, miR34a and miR34b was not significantly different between the 
malignant and non-malignant samples (p=0.968; 0.2; 0.509; 0.603 respectively; Figure 1/A 
and 1/B).  
 
3.3 Diagnostic parameters of selected miRNAs in ovarian cancer 
To determine the diagnostic potential of selected miRNAs, sensitivity, specificity, PPV and 
NPV values were calculated and ROC-AUC curves were constructed based on the expression 
levels obtained in the malignant and healthy samples (Figure 2, Table 2). MiR34c was 
excluded from this analysis because it did not show significantly altered expression between 
these groups. ROC-AUC proved to be the largest in the case of miR200c: 0.861 (95% 
CI=0.776-0.947) (Figure 2, Table 2). Diagnostic accuracy was the highest in the case of 
miR200b (82.95%). MiR200a, miR141 and miR429 had the highest sensitivity (85.71%). 
Specificity proved to be the highest in the case of miR200b (90%). MiR34a showed the 
lowest diagnostic parameters (Figure 2, Table 2).    
We also constructed ROC-AUC curves using the expression data obtained from the non-
malignant and malignant samples for those miRNAs that showed significantly different 
expression between these groups. MiR203a could discriminate patients with malignant tumors 
from patients with non-malignant masses with a power AUC of 0.774 (95% CI=0.598-0.949). 
ROC-AUC proved to be 0.766 (95% CI=0.584-0.949); 0.759 (95% CI=0.556-0.962) and 
0.720 (95% CI=0.547-0.894) in the case of miR141, miR200a and miR429 respectively. 
 
3.4 Comparison of the plasma levels of miRNAs, CA125 and HE4 
Spearman rank correlation analysis was performed to assess possible correlations between the 
expression values of all the tested miRNAs determined in the malignant and healthy samples 
(Table 3/A). Positive correlation was found in all cases. Correlation proved to be the highest 
between miR200b and miR200c (Table 3/A). MiR200 family members showed moderate 
correlation with each other and with miR203a (Table 3/A). Correlation was weaker between 
the members of the miR200 and miR34 family (Table 3/A). It is important to mention that 
miR34a and miR34b showed higher correlation with each other than with miR34c (Table 
3/A). Moreover, the results of miR34c did not prove to be significant in several comparisons 
(Table 3/A).  
We also studied the correlation of expression levels in malignant and non-malignant samples 
in case of those miRNAs that showed significantly different expression in these groups. 
Correlation followed similar tendency in this comparison as well. Positive correlation was 
found in all the cases. The correlation between miR141 and miR429 proved to be moderate (rs 
= 0.591; p<0.001). MiR141 showed slightly higher correlation with miR203a (rs = 0.546; 
p<0.001) and miR200a (rs = 0.555; p<0.001) in this comparison than in the case of the 
malignant and healthy samples. The correlation of miR429 and miR203a also proved to be 
higher (rs = 0.627; p<0.001) in this comparison. The correlation of miR200a was similar with 
miR429 (rs = 0.496; p<0.001) but showed lower value with miR203a in this comparison (rs = 
0.453; p<0.001). 
In some malignant samples (n=21) CA125 and HE4 values were also available (Table 1). 
Cohen’s kappa (κ) values were calculated in these malignant samples in order to determine 
the agreement between the diagnostic tests based on selected miRNAs and the standard 
CA125 or HE4 markers (Table 4). The agreement was the highest between miR200b and 
miR200c. The agreement proved to be good between miR200c and miR34b. The agreement 
was moderate in several other cases between the miRNAs. HE4 showed moderate agreement 
with miR200b, miR200c and CA125. However, the agreement proved to be weak between the 
miRNAs and CA125 (Table 4). 
 
3.5 Target analysis of miRNAs 
In order to study the functional connections between the miRNAs by revealing their mRNA 
interaction partners bioinformatic tools were applied. Experimentally validated target genes 
shared by 2 miRNAs were analyzed by miRTargetLink. All gene lists and annotations are 
presented in the Supplementary table. Functional enrichment analysis was also performed to 
recognize the most significant enriched disease, GO terms and KEGG pathways associated 
with the miRNA target sets (p<0.05). In the Supplementary table only those hits are presented 
that are directly linked to cancer progression. 
MiR200 family members are heavily interconnected through several common targets (Table 
3/B). 59 target genes are shared by at least 2 members of this family (Supplementary table). 
Gene enrichment analysis revealed that these target genes are enriched in ovarian cancer (fold 
enrichment 7.2), in the regulation of endothelial cell migration (fold enrichment 26.07) and in 
several pathways involved in cancer (Supplementary table). Most of the targets are shared by 
miR200b and miR200c (Table 3/B; Supplementary table). These targets are also enriched in 
ovarian cancer (fold enrichment 5.39) and GO enrichment analysis revealed that the common 
target genes are highly enriched in the positive regulation of endothelial cell migration (fold 
enrichment 34.77). 
MiR34 family members regulate 20 shared target genes (Supplementary table). Fold 
enrichment scores of these target genes proved to be higher in ovarian cancer (12.91) than that 
of the shared targets of miR200 family members. These genes are highly enriched in the 
regulation of epithelial to mesenchymal transition (fold enrichment 101.77). It is important to 
note that miR34a and miR34b share higher number of targets with each other than with 
miR34c (Table 3/B). 
The interactions between the miR200 and miR34 family members or with miR203a seem to 
be weaker according to the lower number of shared target genes (Table 3/B, Supplementary 
table). 
 
4. Discussion 
An intriguing but poorly understood aspect of miRNAs is their presence in body fluids. Their 
appearance in blood shows correlation with the presence of numerous malignancies and 
proved to be reliable biomarkers in the diagnosis or prognosis of cancer (Hayes et al., 2014; 
Kinose et al., 2014). Ovarian cancer has relatively high mortality among women that is mostly 
due to the fact that in the majority of the patients the disease is diagnosed at advanced stage 
when the survival rate is only 5-21% (Jelovac and Armstrong, 2011). Developing a minimally 
invasive and highly accurate diagnostic method would facilitate the diagnosis of ovarian 
cancer, which would also contribute to the improvement of survival chances. Here we studied 
the accuracy of circulating miRNAs in the diagnosis of ovarian cancer in a Caucasian 
(Hungarian) cohort. 
We screened the expression level of 9 miRNAs in the plasma samples of patients with 
malignant or non-malignant ovarian tumors, and in age-matched healthy controls. Based on 
our results miR200 family members proved to be promising biomarkers in the diagnosis of 
ovarian cancer. MiR200 family members are addressed to play crucial role in the regulation of 
cancer initiation, angiogenesis and metastasis (Choi and Ng, 2017). The dysregulation of 
miR200 family members is well-known in cancer and their circulating counterparts proved to 
be reliable diagnostic and prognostic markers in breast, prostate, lung, bladder or colorectal 
cancer (Feng et al., 2014; Liu et al., 2016; Larrea et al., 2018). Their expression is 
dysregulated in ovarian cancer as well and they are reported to be associated with disease 
stage, tumor subtypes, chemosensitivity and prognosis (Koutsaky et al., 2017). In accordance 
with our results circulating miR200 family members proved to be promising biomarkers in 
ovarian cancer in previous studies (Kan et al., 2012; Kapetanakis et al., 2015;  Gao and Wu, 
2015; Zuberi et al., 2015; Meng et al., 2015; Halvorsen et al.,2017; Pendelbury et al., 2017). 
To the best of our knowledge this is the first study that investigates circulating miR200s in a 
Central European population. 
According to our results high levels of circulating miR34a and miR34b were also associated 
with ovarian cancer among which miR34b showed better diagnostic properties. MiR34 family 
members are well known to regulate cell cycle, apoptosis and invasiveness in cancer (Li et al., 
2014). These miRNAs proved to have direct role in the development of breast, prostate, 
bladder or brain cancer and miR34a is considered to be a promising therapeutic target in 
cancer treatment (Li et al., 2014). Elevated level of circulating miR34a and miR34b was 
reported in breast, lung and prostate cancer (Lodes et al., 2009; Roth et al., 2010; 2011). Their 
aberrant expression was also confirmed in ovarian carcinoma samples (Iorio et al., 2007;  
Zhang et al., 2008; Lee et al., 2009; Corney et al., 2010; Schmid et al., 2016). However, 
limited information is available about circulating miR34 family members in ovarian cancer. 
Only miR34c was under investigation previously and it was upregulated in cancer patients 
(Ayaz et al., 2014) – in contrast to our results. 
We also detected significantly elevated expression level of miR203a in the plasma samples of 
patients with malignant ovarian tumor. MiR203 is a putative tumor suppressor and regulates 
tumor cell proliferation, invasion and angiogenesis. Its aberrant expression was confirmed in 
breast, colorectal, prostate cancer or in melanoma (Shao et al., 2017). Higher circulating 
miR203 level was reported in breast and colorectal cancer (Madhavan et al., 2016; Hur et al., 
2017). Its aberrant expression was also confirmed in ovarian carcinoma samples (Iorio et al., 
2007; Lee et al., 2009; Wymann et al., 2009; Wang et al., 2013; Azizmohammadi et al., 
2016). However, the application of circulating miR203 as a diagnostic marker in ovarian 
cancer is understudied. Circulating exosomal miR203 level was found to be elevated in the 
sera of patients with malignant tumors compared to the sera of patients with benign disease 
(Taylor and Gercel-Taylor, 2008). However, miR203 level was not compared with healthy 
controls in this study (Taylor and Gercel-Taylor, 2008). 
One major advantage of the utilization of circulating biomarkers is that when a pelvic mass is 
present in patients the detection of these markers strengthens the suspicion of ovarian 
carcinoma. In order to identify those miRNAs that might be applicable in the differential 
diagnosis of non-malignant samples we also compared the expression level of miRNAs 
between malignant and non-malignant samples. In this comparison less miRNAs proved to be 
significant than when the samples of healthy volunteers were used as controls. These results 
suggest the followings:  i) elevated miR200a, miR141, miR429 and miR203a levels might be 
reliable biomarkers in the discrimination of non-malignant masses from malignant tumors; ii) 
non-malignant samples might not be applicable as controls because comparison of malignant 
samples to non-malignants might produce different results than using healthy samples as 
controls. However, further studies are needed to strengthen this hypothesis with larger 
samples size.  
We also studied the agreement between the diagnostic tests based on miRNAs and the 
standard biomarkers CA125 and HE4. Although the agreement of some miRNAs was 
moderate with HE4 they showed weak agreement with CA125. However, higher agreement 
was observed between the diagnostic tests based on miRNAs. The Cohen’s kappa coefficient 
was the highest between the diagnostic tests based on miR200b and miR200c. We have to 
note that this analysis was performed only in the case of malignant samples. Previous 
publications that studied the correlation between miRNAs and CA125 showed controversial 
results. According to some publications circulating miRNA levels are not consistent with 
CA125 (Resnick et al., 2009; Kapetanakis et al., 2015) but others suggest positive correlation 
(Meng et al., 2015; 2016). This discrepancy might be explained by the fact that the diagnostic 
properties of CA125 are far from perfect (Montagnana et al., 2017) that is also true for single 
miRNAs. It is important to note that multivariate diagnostic tests that combine circulating 
miRNAs with CA125 or HE4 had higher efficiency than single tests in several studies (Elias 
et al., 2017; Montagnana et al., 2017; Ren et al., 2018, Shah et al., 2018). We conclude that 
miR200 family members, miR203a and miR34b are promising candidates for multivariate 
diagnostic tests based on the combination of miRNAs with each other or with CA125 and 
HE4 markers. Further studies are needed with higher sample size in order to strengthen this 
hypothesis.  
We also studied the regulatory relationship of these miRNAs through assessing their shared 
target genes and by calculating the correlation between their expression levels. We found high 
agreement between the correlation of their plasma level and the number of target genes they 
share. Strong positive correlation was identified between the members of the miR200 family, 
among which miR200b and miR200c expression levels showed the highest correlation 
coefficient. Target analysis revealed that these miRNAs co-regulate several genes involved in 
cancer progression. Similar phenomenon was observed in the case of miR34a and miR34b. It 
is also important to note that weaker correlation was found between those miRNAs that 
shared less targets e.g. between miR34 and miR200 family members or between miR34b and 
miR34c. Our results suggest that the expression and extracellular trafficking of those miRNAs 
that are tightly connected through shared targets in miRNA-target gene interaction networks 
might be co-regulated. This regulation might be facilitated by the formation of exosomes that 
proved to be important in the delivery of these miRNAs according to previous results (Taylor 
and Gercel-Taylor, 2008). It is also important to note that the release of miRNAs – partly 
through the formation of exosomes – seems to be under active regulation (Collino et al., 
2010). Our further aim is to shed light on the molecular details of this regulation that might 
lead to the development of more efficient diagnostic tests in ovarian cancer. 
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Figure legends 
Figure 1 Plasma level of miRNAs.  
A) Scatter plot of miR200 family members for patients with malignant tumor (M), non-
malignant masses (NM) and in healthy controls (H).  
B) Scatter plot of miR34 family members and miR203a for patients with malignant tumor 
(M), non-malignant masses (NM) and in healthy controls (H). 
 
Figure 2 ROC curves of miRNAs. 
 
Supplementary table 
Annotation of experimentally validated target genes that are shared by at least 2 members of 
the miR200 family (page 1), by miR200b and miR200c (page 2), by at least 2 members of the 
miR34 family (page 3), by at least 1 member of the miR200 family with at least 1 member of 
the miR34 family (page 4), by at least 1 member of the miR200 family with miR203a (page 
5), or by at least 1 member of the miR34 family with miR203a (page 6). Enrichment analysis 
is also presented including the most significantly enriched disease, GO terms and KEGG 
pathways associated with the miRNA target sets (p<0.05). 
Table 1 Clinical characteristics of patients with malignant ovarian tumor, non-malignant 
ovarian masses and healthy volunteers in the study. 
 
Parameter  Malignant Non-malignant  Healthy control 
Age (years)  57.03 ± 9.56 57.27 ± 11.76 56.17 ± 12.18 
Histological type     
Cystadenocarcinoma 
papillare serosum 
 21   
Cystadenocarcinoma 
serosum 
 3   
Adenocarcinoma 
papillare serosum 
 2   
Cysta serosa simplex   3  
Cystadenoma 
serosum 
  2  
Cystadenoma 
mucinosum 
  1  
Cystadenofibroma 
serosum 
  2  
Fibroma ovarii   1  
Ovarium fibrosis   1  
Salpingitis chr. 
fibrosa 
  1  
Cysta follicularis   1  
FIGO stage I. 3   
 a 2   
 c 1   
 III. 18   
 a 2   
 b 3   
 c 13   
 IV. 7   
 b 4   
 c 1   
Prior cancer  2   
CA125 level (kU/l)  26 11  
≤35  3 8  
>35  23 3  
HE4 level (pmol/l)  21 10  
≤70  4 4  
>70  17 6  
 
 Table 2 Diagnostic parameters of miRNAs 
 
 AUC Diagnostic 
accuracy 
Sensitivity Specificity PPV NPV 
miR200a 0.845 
 
84.09% 71.43% 90% 76.92% 87.1% 
miR200b 0.822 
 
82.95% 67.86% 90% 76% 85.71% 
miR200c 0.861 
 
81.82% 71.43% 86.67% 71.43% 86.67% 
miR141 0.825 
 
81.82% 85.71% 80% 66.67% 92.31% 
miR429 0.791 
 
77.27% 64.29% 83.33% 64.29% 83.33% 
miR203a 
 
0.831 
 
84.09% 82.14% 85% 71.88% 91.07% 
miR34a 0.655 
 
60.23% 57.14% 61.67% 41.03% 75.51% 
miR34b 0.832 
 
73.86% 71.43% 75% 57.14% 84.91% 
28 
 
Table 3 Interactions between miRNAs. 1 
A: Spearman’s rank correlation coefficients (rs) between the expression levels of miRNAs. # p>0.05. In all the other cases p<0.05  2 
B: Number of validated target genes shared by miRNAs. The analysis was performed by miRTargetLink. 3 
 4 
 
miR200a  miR200b  miR200c  miR141  miR429  miR203a  miR34a  miR34b  miR34c  
miR200a  -  0.609  0.590  0.463  0.436  0.541  0.324  0.325  0.099# 
miR200b  25 -  0.774  0.554  0.423  0.650  0.474  0.284  0.290  
miR200c  23  43  -  0.497  0.453  0.673  0.378  0.363  0.209# 
miR141  23  19  19  -  0.616  0.471  0.399  0.415  0.192# 
miR429  22  24  21  18  -  0.446  0.470  0.351  0.264  
miR203a  4  5  5  3  1  -  0.315  0.241  0.162# 
miR34a  3  7  6  2  4  7  -  0.384  0.276  
miR34b  1  4  3  0 3 4 19  -  0.018# 
miR34c  1 1  0 0 0 0 2 0 -  
 5 
6 
A 
B 
29 
 
 7 
Table 4 Cohen’s kappa values (κ ) between the pairwise comparison of the agreement between the diagnostic tests based on miRNAs and CA125 8 
or HE4.  9 
  miR200a  miR200b  miR200c  miR141  miR429  miR203a  miR34a  miR34b  CA125  HE4  
miR200a  -  0.529  0.375  0.173  0.475  0.391  0.316  0.077  0.385  <0.01   
miR200b  0.529  -  0.886  0.087  0.538  0.5  0.516  0.571  <0.01  0.39  
miR200c  0.375  0.886  -  0.125  0.386  0.314  0.417  0.667  0.028  0.474  
miR141  0.173  0.087  0.125  -  0.504  0.323  <0.01   0.087  0.323  <0.01 
miR429  0.475  0.538  0.386  0.504  -  0.696  0.121  0.308  0.087  0.013  
miR203a  0.391  0.5  0.314  0.323  0.696  -  0.31  0.25  <0.01 <0.01   
miR34a  0.316  0.516  0.417  <0.01   0.121  0.31  -  0.516  <0.01   0.019  
miR34b  0.077  0.571  0.667  0.087  0.308  0.25  0.516  -  <0.01   0.16  
CA125  0.385  <0.01   0.39  0.323  0.087  <0.01   <0.01 <0.01   -  0.483  
HE4  <0.01   0.39  0.474  <0.01   0.013  <0.01   0.019  0.16  0.483  -  
 10 
30 
 
Figure 1 11 
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Figure 2 14 
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